217 related articles for article (PubMed ID: 9642449)
1. Prognostic significance of DNA ploidy and S-phase fraction in malignant serous cystadenocarcinoma of the ovary.
Bakshi N; Rajwanshi A; Patel F; Ganguly NK
Anal Quant Cytol Histol; 1998 Jun; 20(3):215-20. PubMed ID: 9642449
[TBL] [Abstract][Full Text] [Related]
2. Multivariate analysis of the prognostic significance of DNA-ploidy and S-phase fraction in ovarian cancer determined by flow cytometry following detection of cytokeratin-labeled tumor cells.
Kimmig R; Wimberger P; Hillemanns P; Kapsner T; Caspari C; Hepp H
Gynecol Oncol; 2002 Jan; 84(1):21-31. PubMed ID: 11748971
[TBL] [Abstract][Full Text] [Related]
3. Cell proliferation in ovarian carcinoma: superior accuracy of S-phase fraction (SPF) by DNA labeling index versus flow cytometric SPF, lack of independent prognostic power for SPF and DNA ploidy, and limited effect of SPF on tumor growth rate.
Meyer JS; Gersell DJ; Yim S
Gynecol Oncol; 2001 Jun; 81(3):466-76. PubMed ID: 11371140
[TBL] [Abstract][Full Text] [Related]
4. Tumor DNA ploidy and prognosis of patients with serous cystadenocarcinoma of the ovary.
Kigawa J; Minagawa Y; Ishihara H; Kanamori Y; Terakawa N
Cancer; 1993 Aug; 72(3):804-8. PubMed ID: 8334634
[TBL] [Abstract][Full Text] [Related]
5. Flow cytometric DNA ploidy and S-phase heterogeneity in advanced ovarian carcinoma.
Kaern J; Tropé CG; Kristensen GB; Pettersen EO
Cancer; 1994 Apr; 73(7):1870-7. PubMed ID: 8137213
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of DNA ploidy, S-phase fraction, and P-glycoprotein expression in colorectal cancer.
Salud A; Porcel JM; Raikundalia B; Camplejohn RS; Taub NA
J Surg Oncol; 1999 Nov; 72(3):167-74. PubMed ID: 10562364
[TBL] [Abstract][Full Text] [Related]
7. Value of DNA ploidy and S-phase fraction as prognostic factors in stage III cutaneous melanoma.
Martin G; Halwani F; Shibata H; Meterissian S
Can J Surg; 2000 Feb; 43(1):29-34. PubMed ID: 10714254
[TBL] [Abstract][Full Text] [Related]
8. Ovarian tumors of low malignant potential. Correlation of DNA index and S-phase fraction with histopathologic grade and clinical outcome.
Demirel D; Laucirica R; Fishman A; Owens RG; Grey MM; Kaplan AL; Ramzy I
Cancer; 1996 Apr; 77(8):1494-500. PubMed ID: 8608534
[TBL] [Abstract][Full Text] [Related]
9. Flow and image cytometric DNA ploidy, including 5c exceeding cells, of serous borderline malignant ovarian tumors. Correlation with clinicopathologic characteristics.
Flezar MS; But I; Kavalar R; Us-Krasovec M
Anal Quant Cytol Histol; 2003 Jun; 25(3):139-45. PubMed ID: 12882085
[TBL] [Abstract][Full Text] [Related]
10. Granulosa cell tumor of ovary: a clinicopathologic and flow cytometric DNA analysis.
Roush GR; el-Naggar AK; Abdul-Karim FW
Gynecol Oncol; 1995 Mar; 56(3):430-4. PubMed ID: 7705680
[TBL] [Abstract][Full Text] [Related]
11. Flow cytometric analysis of uterine sarcoma: ploidy and S-phase rate as prognostic indicators.
Malmström H; Schmidt H; Persson PG; Carstensen J; Nordenskjöld B; Simonsen E
Gynecol Oncol; 1992 Feb; 44(2):172-7. PubMed ID: 1544595
[TBL] [Abstract][Full Text] [Related]
12. DNA flow cytometric analysis of primary operable breast cancer. Relation of ploidy and S-phase fraction to outcome of patients in NSABP B-04.
Fisher B; Gunduz N; Costantino J; Fisher ER; Redmond C; Mamounas EP; Siderits R
Cancer; 1991 Oct; 68(7):1465-75. PubMed ID: 1893345
[TBL] [Abstract][Full Text] [Related]
13. Prognostic importance of DNA ploidy and p53 in early stages of epithelial ovarian carcinoma.
Skirnisdóttir I; Sorbe B; Karlsson M; Seidal T
Int J Oncol; 2001 Dec; 19(6):1295-302. PubMed ID: 11713603
[TBL] [Abstract][Full Text] [Related]
14. Cell cycle flow cytometric analysis in the diagnosis and management of colorectal carcinoma.
Sampedro A; Salas-Bustamante A; López-Artimez M; García-Muñíz JL; Urdiales G
Anal Quant Cytol Histol; 1999 Aug; 21(4):347-52. PubMed ID: 10560513
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of DNA ploidy and S-phase fraction in stage I endometrial carcinoma.
Pfisterer J; Kommoss F; Sauerbrei W; Rendl I; Kiechle M; Kleine W; Pfleiderer A
Gynecol Oncol; 1995 Aug; 58(2):149-56. PubMed ID: 7622098
[TBL] [Abstract][Full Text] [Related]
16. DNA flow cytometry, clinical and morphological parameters as prognostic factors for advanced malignant and borderline ovarian tumors.
Kühn W; Kaufmann M; Feichter GE; Rummel HH; Schmid H; Heberling D
Gynecol Oncol; 1989 Jun; 33(3):360-7. PubMed ID: 2722063
[TBL] [Abstract][Full Text] [Related]
17. Gross genomic alterations differ between serous borderline tumors and serous adenocarcinomas--an image cytometric DNA ploidy analysis of 307 cases with histogenetic implications.
Pradhan M; Davidson B; Tropé CG; Danielsen HE; Abeler VM; Risberg B
Virchows Arch; 2009 Jun; 454(6):677-83. PubMed ID: 19421773
[TBL] [Abstract][Full Text] [Related]
18. Influence of cellular DNA content on survival in ovarian carcinoma.
Klemi PJ; Joensuu H; Mäenpää J; Kiilholma P
Obstet Gynecol; 1989 Aug; 74(2):200-4. PubMed ID: 2748056
[TBL] [Abstract][Full Text] [Related]
19. [A quantitative study on nuclear DNA content and morphological parameters in ovarian cystadenocarcinoma].
Liu C; Zhao Y; Sun X
Zhonghua Fu Chan Ke Za Zhi; 1995 Dec; 30(12):738-40. PubMed ID: 8728920
[TBL] [Abstract][Full Text] [Related]
20. Flow cytometry and AgNORs in benign, borderline, and malignant mucinous and serous tumours of the ovary.
Griffiths AP; Cross D; Kingston RE; Harkin P; Wells M; Quirke P
Int J Gynecol Pathol; 1993 Oct; 12(4):307-14. PubMed ID: 8253547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
